GlassScriptPhysician profile
Jacob Fuqua
NPI 1518490499
$1,817.21
in general payments reported to CMS, 2019-2025
26 companies · $751 in 2025
The $751 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $278 · 2023: $99.07 · 2024: $688 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $440.23 | 2022-2024 | Lumakras |
| Janssen Biotech, INC. | $313.85 | 2023-2025 | Tecvayli, Erleada, Akeega |
| Celgene Corporation | $167.20 | 2024-2025 | Abecma, Reblozyl |
| Blueprint Medicines Corporation | $109.32 | 2024 | |
| Alexion Pharmaceuticals, INC. | $87.95 | 2022 | |
| Tempus Ai, INC | $79.95 | 2024 | |
| Merck Sharp & Dohme LLC | $73.74 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Abbvie INC. | $60.23 | 2025 | |
| Novartis Pharmaceuticals Corporation | $53.74 | 2025 | |
| Incyte Corporation | $50.36 | 2025 | Monjuvi, Zynyz |
| Alnylam Pharmaceuticals INC. | $48.02 | 2025 | Givlaari, Onpattro |
| Geron Corporation | $41.89 | 2025 | Rytelo |
| Astrazeneca Pharmaceuticals LP | $38.76 | 2025 | Lynparza, Tagrisso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.50 | 2025 | |
| Genzyme Corporation | $27.49 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.61 | 2025 | Fruzaqla |
| Accord Healthcare, INC. | $21.37 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $20.66 | 2025 | Lynozyfic |
| Tersera Therapeutics LLC | $20.10 | 2025 | Zoladex |
| Daiichi Sankyo INC. | $16.80 | 2025 | Enhertu |
| Kyowa Kirin, INC. | $16.76 | 2025 | |
| Immunocore Limited | $16.40 | 2025 | Kimmtrak |
| Genentech USA, INC. | $16.03 | 2025 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $14.92 | 2025 | |
| Array Biopharma INC | $14.23 | 2025 | Braftovi, Tukysa, Mektovi |
| Recordati_rare_diseases_inc. | $14.10 | 2025 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Fuqua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.